The shares of a prominent healthcare company gained up to 4 percent in today’s trading session after a foreign institutional investor, like Société Générale, East Bridge Capital, and others, bought 58.76 lakh equity shares via a Bulk deal.
With a market capitalization of Rs 14,588.93 crore, the shares of Indegene Ltd were trading at Rs 607.70 per share, increasing around 3.02 percent as compared to the previous closing price of Rs 589.90 apiece.
Block Deal
The shares of Indegene Ltd have seen positive movement after foreign institutional investors, like Société Générale, East Bridge Capital, and Smallcap World Fund, bought 58.76 lakh equity shares via a Bulk deal.
However, CA Dawn Investments, a foreign institutional investor, offloaded a 10.2 percent stake (2.44 crore equity shares) via a Bulk deal at a floor price of Rs 591.5 per share, which is valued at approximately Rs 1,447 crore, further, Abakkus Emerging Opportunities Fund & PI Opportunities AIF also bought 29.02 equity shares together in same deal. According to the March 2025 shareholding details, Ca Dawn Investments holds 2,44,75,402 equity shares, which is equivalent to a 10.2 percent stake in Indegene.
Financial & operational Highlights
Looking forward to the company’s financial performance, revenue increased by 12 percent from Rs 673 crore in Q4FY24 to Rs 756 crore in Q4FY25. Further, during the same time frame, net profit increased by 24 percent from Rs 95 crore to Rs 118 crore.
The company maintains 73 active client relationships, with 41 clients contributing over $1 million in revenue. It derives 66 percent of its revenue from the top 20 global biopharma firms. With 4,961 employees (4,268 in delivery), 23.8 percent have healthcare expertise, and its voluntary attrition rate stands at 16.6 percent.
Indegene Limited provides digital-led commercialization services for the life sciences industry, specifically catering to biopharmaceutical, emerging biotech, and medical devices companies. The company assists in drug development, clinical trials, pharmacovigilance, regulatory submissions, complaints management, and sales/marketing.
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
